# Concentra Group Holdings (CON) Stock Analysis: Strong Buy Ratings and a 6.60% Potential Upside

- Link: https://www.directorstalkinterviews.com/concentra-group-holdings-con-stock-analysis-strong-buy-ratings-and-a-6-60-potential-upside/4121257159
- Published: 2026-07-21T10:16:23+01:00
- Author: Madison Wilson

Concentra Group Holdings Parent, Inc. (CON), a prominent player in the healthcare
sector, particularly in the medical care facilities industry, is capturing the attention
of investors with its robust performance metrics and promising stock potential. 
Headquartered in Addison, Texas, this company has carved a niche in providing occupational
health services across the United States. Its comprehensive service offerings range
from occupational health and employer-sponsored primary care to cutting-edge telemedicine
solutions.

With a market capitalization of $4.01 billion, Concentra is not just a major force
in its industry but also a potentially lucrative investment opportunity. Currently
trading at $31.31, the stock has shown resilience, with a 52-week high of $31.91
and a low of $18.71. The company’s revenue growth of 13.70% underscores its capacity
to expand its service offerings and client base effectively.

One of the standout features for investors is Concentra’s impressive Return on Equity(
ROE) of 47.00%. Such a high ROE indicates that the company is highly efficient in
generating profits from its equity base, a critical indicator of financial health
and operational efficiency. Additionally, the company boasts a free cash flow of
$143.36 million, providing it with the flexibility to invest in growth opportunities,
pay dividends, or reduce debt.

Concentra’s forward P/E ratio of 18.52 suggests that the stock is reasonably priced
relative to its earnings expectations, making it an appealing choice for growth-
oriented investors. While traditional valuation metrics like PEG and Price/Book 
ratios are unavailable, the company’s earnings per share (EPS) of 1.38 provides 
a snapshot of its profitability.

The company also offers a modest dividend yield of 0.79%, with a conservative payout
ratio of 17.99%. This provides income-seeking investors with a steady, albeit small,
return on investment while allowing the company to retain earnings for future expansion.

Analysts are overwhelmingly bullish on Concentra, with all nine ratings being a ‘
Buy’ and no ‘Hold’ or ‘Sell’ ratings. This consensus indicates strong confidence
in the company’s future performance. The target price range of $28.00 to $37.00,
with an average target of $33.38, suggests a potential upside of 6.60%, making it
a compelling addition to growth-focused portfolios.

Technical indicators further bolster the bullish sentiment. The stock’s 50-day and
200-day moving averages are $27.84 and $22.93, respectively, indicating that Concentra
is trading well above these averages, a positive signal of upward momentum. The 
Relative Strength Index (RSI) of 67.01, while approaching overbought territory, 
suggests strong investor interest and demand. Moreover, the slightly negative MACD
signal line, at 1.10 compared to the MACD of 1.26, indicates a bullish trend that
investors might find promising.

In an era where healthcare services are increasingly indispensable, Concentra Group
Holdings stands out with its diverse range of services, from injury care and drug
screenings to telemedicine and pharmacy solutions. As it continues to innovate and
expand its market presence, Concentra offers a unique blend of growth potential 
and financial stability. For investors seeking exposure in the healthcare sector,
CON could be a strategic addition to their portfolio, capitalizing on the company’s
growth trajectory and the favorable analyst outlook.

Share on:
